Advanced

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.

Sander, Frida Ewald; Rydström, Anna; Bernson, Elin; Kiffin, Roberta; Riise, Rebecca; Aurelius, Johan; Anderson, Harald LU ; Brune, Mats; Foà, Robin and Hellstrand, Kristoffer, et al. (2016) In Oncotarget
Abstract
Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8+ (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older... (More)
Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8+ (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8+ T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oncotarget
publisher
Impact Journals, LLC
external identifiers
  • PMID:26863635
  • Scopus:84958779561
ISSN
1949-2553
DOI
10.18632/oncotarget.7210
language
English
LU publication?
yes
id
df9c01bb-63aa-4b6c-9d67-ca8ade09c469 (old id 8825873)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26863635?dopt=Abstract
date added to LUP
2016-03-03 14:37:17
date last changed
2016-10-13 04:30:58
@misc{df9c01bb-63aa-4b6c-9d67-ca8ade09c469,
  abstract     = {Preventing relapse after chemotherapy remains a challenge in acute myeloid leukemia (AML). Eighty-four non-transplanted AML patients in first complete remission received relapse-preventive immunotherapy with histamine dihydrochloride and low-dose interleukin-2 in an international phase IV trial (ClinicalTrials.gov; NCT01347996). Blood samples were drawn during cycles of immunotherapy and analyzed for CD8+ (cytotoxic) T cell phenotypes in blood. During the first cycle of therapy, a re-distribution of cytotoxic T cells was observed comprising a reduction of T effector memory cells and a concomitant increase of T effector cells. The dynamics of T cell subtypes during immunotherapy prognosticated relapse and survival, in particular among older patients and remained significantly predictive of clinical outcome after correction for potential confounders. Presence of CD8+ T cells with specificity for leukemia-associated antigens identified patients with low relapse risk. Our results point to novel aspects of T cell-mediated immunosurveillance in AML and provide conceivable biomarkers in relapse-preventive immunotherapy.},
  author       = {Sander, Frida Ewald and Rydström, Anna and Bernson, Elin and Kiffin, Roberta and Riise, Rebecca and Aurelius, Johan and Anderson, Harald and Brune, Mats and Foà, Robin and Hellstrand, Kristoffer and Thorén, Fredrik B and Martner, Anna},
  issn         = {1949-2553},
  language     = {eng},
  month        = {02},
  publisher    = {ARRAY(0x8e2cc30)},
  series       = {Oncotarget},
  title        = {Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.},
  url          = {http://dx.doi.org/10.18632/oncotarget.7210},
  year         = {2016},
}